

DEMOGRAPHIC AND PERSONAL INFORMATION

ray.dorsey@jhmi.edu

EDUCATION AND TRAINING

BS Stanford University, Stanford, CA; Biological sciences
MD University of Pennsylvania School of Medicine, Philadelphia, PA
MBA The Wharton School, University of Pennsylvania, Philadelphia, PA; Health care management

PROFESSIONAL EXPERIENCE

Intern; U.S. Health Care Financing Administration (now the Centers for Medicare & Medicaid Services), Washington, DC
Intern; Robert Wood Johnson Foundation, Princeton, NJ
1998 Investment banking summer associate; Health Care Group, Credit Suisse First Boston, Chicago, IL
1999-2001 Associate; McKinsey & Company, Chicago, IL
2001-02 Medicine Intern; Evanston Hospital, Evanston Northwestern Healthcare, Evanston, IL
2002-05 Neurology Resident; University of Pennsylvania Medical Center, Philadelphia, PA
Fellow in movement disorders and experimental therapeutics; University of Rochester, Rochester, NY
2005-06 Instructor; Department of Neurology, University of Rochester, Rochester, NY
2006-07 Senior Instructor; Department of Neurology, University of Rochester, Rochester, NY
2007-10 Assistant professor; Department of Neurology, University of Rochester, Rochester, NY
2010-present Associate professor; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD
2010-present Director of movement disorders division, Johns Hopkins School of Medicine, Baltimore, MD
2010-present Director of neurology telemedicine, Johns Hopkins School of Medicine, Baltimore, MD

RESEARCH ACTIVITIES

Peer-Reviewed Publications

1. **Dorsey ER**, Jarjoura D, Rutecki GW. Influence of controllable lifestyle on recent trends in specialty choice by US medical students. JAMA 2003;290:1173-8. Erratum in JAMA 2003;290:2666. [PMID: 12952999]
2. **Dorsey ER**, Jarjoura D, Rutecki GW. The influence of controllable lifestyle and sex on the specialty choices of graduating U.S. medical students, 1996-2003. Acad Med 2005;80:791-6. [PMID: 16123455]
3. Moses H, **Dorsey ER**, Matheson DH, Thier SO. Financial anatomy of biomedical research. JAMA 2005;294:1333-42. [PMID: 16174691]
4. **Dorsey ER**, Nincic D, Schwartz JS. Costs of medical education: an evaluation of four approaches to reduce the financial burden of medical education. Acad Med 2006;81:245-51. [PMID: 16501266]
5. **Dorsey ER**, Holloway RG, Ravina BM. Biomarkers in Parkinson's disease. Expert Rev of Neurotherapeutics 2006;6:823-31. [PMID: 16784406]
6. **Dorsey ER**, Raphael BA, Balcer LJ, Galetta SL. Predictors of future publication record and academic rank in a cohort of neurology residents. Neurology 2006;67:1335-7. [PMID: 17060557]
7. **Dorsey ER**, Vitticore P, de Roulet J, Thompson JP, Carrasco M, Johnston SC, Holloway RG, Moses H. Financial anatomy of neuroscience research. Ann Neurol 2006;60:652-9. [PMID: 17192926]

8. **Dorsey ER**, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson's disease in the most populous nations, 2005 – 2030. *Neurology* 2007;68:384-6. [PMID: 17082464]
9. **Dorsey ER**, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. *Neurology* 2007;68:1524-8. [PMID: 17470756]
10. Thompson JP, Noyes K, **Dorsey ER**, Schwid SR, Holloway RG. A quantitative risk-benefit analysis of natalizumab. *Neurology* 2008;71:357-64. [PMID: 18663181]
11. Oster E, **Dorsey ER**, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K for the Huntington Study Group PHAROS Investigators. Fear of health insurance loss among individuals at risk for Huntington disease. *Am J Med Genet Part A* 2008;146A:2070-7. [PMID: 18627059]
12. Mauldin PD, Guimaraes P, Albin RL, **Dorsey ER**, Bainbridge JL, Siderowf A for NINDS NET-PD Investigators. Optimal Frequency for Measuring Healthcare Utilization in Parkinson's Disease Using Participant Recall: The FS-TOO Resource Utilization Sub-Study. *Clinical Therapeutics* 2008;30:1553-7. [PMID: 18803996]
13. Huntington Study Group TREND-HD Investigators (**Dorsey ER** – corresponding author). Randomized, controlled trial of ethyl-EPA in Huntington disease. *Arch Neurol* 2008;65:1582-9. [PMID: 19064745]
14. **Dorsey ER**, Beck CA, Adams M, Chadwick G, de Bleeck EA, McCallum C, Briner L, Deuel L, Clarke A, Stewart R, Shoulson I, and the Huntington Study Group TREND-HD Investigators. Communicating clinical trial results to research participants. *Arch Neurol* 2008;65:1590-5. [PMID: 19064746]
15. **Dorsey ER**, Van Wuyckhuse BC, Beck CA, Passalacqua WP, Guzick DS. Economics of new faculty hires in basic science. *Acad Med* 2009;84:26-31. [PMID: 19116473]
16. **Dorsey ER**, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H. Funding of Parkinson research from industry and U.S. federal and foundation sources. *Movement Disorders* 2009;24:731-7. [PMID: 19133662]
17. Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M, George BP, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, **Dorsey ER**. Telemedicine for the care of nursing home residents with Parkinson disease. *Movement Disorders* 2009;24:1073-1076. [PMID: 19353687]
18. **Dorsey ER**, Thompson JP, Dayoub E, George B, Saubermann LA, Holloway R. Selegiline shortage: causes and costs of a generic drug shortage. *Neurology* 2009;73:213-7. [PMID: 19620609]
19. **Dorsey ER**, Thompson JP, Carrasco M, de Roulet J, Vitticore P, Nicholson S, Johnston SC, Holloway RG, Moses H, III. Financing and productivity of biomedical research across therapeutic areas. *PLoS One* 4(9): e7015. doi:10.1371/journal.pone.0007015. [PMID: 19750225]
20. Mitsumoto J, **Dorsey ER**, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. *Ann Neurol* 2009;66:184-90. [PMID: 19743448]
21. **Dorsey ER**, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box warnings on atypical antipsychotic medication use. *Arch Intern Med* 2010;170:96-103. [PMID: 20065205]
22. **Dorsey ER**, de Roulet J, Thompson JP, Reminick JI, Thai A, White-Stellato Z, Beck CA, George BP, Moses H. Funding of US biomedical research, 2003 – 2008. *JAMA* 2010;303:137-43. [PMID: 20068207]
23. Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, **Dorsey ER**, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A and the DIMOND Investigators of the Huntington Study Group. A randomized, placebo-controlled trial of latrepiridine in Huntington disease. *Arch Neurol* 2010;67:154-60. [PMID: 20142523]
24. Block RC, **Dorsey ER**, Beck CA, Brenna JT, Shoulson I. Altered cholesterol and fatty acid metabolism in Huntington disease. *Journal of Clinical Lipidology* 2010;4:17-23. [PMID: 20802793]
25. Ravina B, Deuel LM, Siderowf A, **Dorsey ER**. Local IRB review of a multicenter trial: local costs without local context. *Ann Neurol* 2010;67:258-60. [PMID: 20225291]
26. **Dorsey ER**, Deuel LM, Voss TS, Finnigan K, George BP, Eason S, Miller D, Reminick J, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Biglan KM. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson disease. *Movement Disorders* 2010;25:1652-9.
27. **Dorsey ER**, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM. A U.S. survey of patients with Parkinson disease: satisfaction with medical care and support groups. *Movement Disorders* 2010;25:2128-35. [PMID 20533449]

manifest HD, and will give us valuable information about the process and feasibility of such trials in pre-manifest participants.

Role: Steering committee member (0 calendar months)

6/30/07 – 8/9/10		

National Institutes of Health 1 KL2 RR024136-01

University of Rochester Clinical and Translational Science Award (renewable)

KL2 Mentored Career Development Award

Direct costs: \$380,000

The aims of this career development award are the following: (1) to quantify the level and sources of investment in biomedical research; (2) to identify the resulting therapeutic advances; and (3) identify means to improve the productivity of research.

Role: Principal investigator (9.0 calendar months)

© 2006 The Authors

Direct costs: \$1,246,850

A horizontal bar chart consisting of 15 black bars of varying lengths. The bars are arranged vertically, with the longest bar in the center and the shortest bars at the top and bottom. The lengths of the bars vary significantly, with some being nearly full-width and others being very short.

2005-08

Site investigator, randomized controlled trial of dimebon for Huntington disease (DIMOND B)

Principal investigator, pilot, randomized, controlled trial of telemedicine for Parkinson disease in a rural

population (TELE-PD)

Clinical monitor, site investigator, and steering committee member, cooperative Huntington's observational research trial (COHORT)

Co-chair, publications and data use committee, cooperative Huntington's observational research trial (COHORT)

Steering committee member, randomized controlled trial of rasagiline for restless legs syndrome (RAZE-RLS)

Steering committee member, randomized controlled trial coenzyme Q₁₀ in individuals with pre-manifest Huntington disease (PREQUEL)

Steering committee member, randomized, controlled trial of dimebon for Huntington disease (HORIZON)

Educational Publications

Please see research publications numbers 1, 2, 4, and 6.

1. **Dorsey ER**, Holloway RG. Quality of life in epilepsy, multiple sclerosis, and beyond. *Ann Neurol* 2007;62:307-8.
2. **Dorsey ER**, Dorsey JA, Dorsey ER. Higher pay. *Virtual Mentor* 2009;11:406-9. Available at: <http://virtualmentor.ama-assn.org/2009/05/oped1-0905.html>.
3. **Dorsey ER**, Meltzer DO. The economics of comparative effectiveness research. *Neurology* 2010;75:492-3.

4.

Letters

1. Rutecki GW, **Dorsey ER**, Jarjoura D. Lifestyle as a factor in medical students' career choices. Author reply. JAMA 2003;290:2941-2.
2. Moses H, **Dorsey ER**, Matheson DH, Thier SO. Financial anatomy of biomedical research. Author reply. JAMA 2006;295:1000-1.
3. **Dorsey ER**, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kiebertz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson's disease in the most populous nations, 2005 – 2030. Author reply. Neurology 2007;69:223-4.
4. Holloway RG, Thompson JP, Noyes K, **Dorsey ER**, Schwid SR. A quantitative risk-benefit analysis of natalizumab. Author reply. Neurology 2009;72:1791-2.

Book Chapters

1. **Dorsey ER**, Holloway RG, Ravina BM. Status of biological markers. In Parkinson's disease: clinical diagnosis and management. Second edition. Factor SA, Weiner WJ (eds). Demos: New York. 2008.
2. **Dorsey ER**, Siderowf A, Holloway RG. Economics of Parkinson's disease. In Parkinson's disease: clinical diagnosis and management. Second edition. Factor SA, Weiner WJ (eds). Demos: New York. 2008.
3. **Dorsey ER**, Vitticore P, Moses H. Risks and rewards of biologics for the brain. In the Dana's Foundation Cerebrum 2008: emerging ideas in brain science. Read CA (editor). Dana Press: New York. 2008.
4. **Dorsey ER**. Perspective from a neurologist. In Professionalism in medicine: the case-based guide for medical students. Spandorfer J, Pohl C, Nasca T, and Rattner SL (eds). Cambridge University Press: Cambridge, MA. 2010.
5. Voss T, **Dorsey ER**. Vascular parkinsonism. In: Kompoliti K, Verhagen L, editors. Encyclopedia of Movement Disorders. Oxford: Elsevier Press. 2010.
6. **Dorsey ER**, Shoulson I. Huntington disease: clinical experimental therapeutics. In Frontiers in Neuroscience. Lo DC, Hughes RE (eds). Taylor and Francis Group: Boca Raton, FL. 2011.

Working Papers

1. Oster E, Shoulson I, Quaid K, **Dorsey ER** on behalf of the Huntington Study Group PHAROS Investigators. Genetic adverse selection: evidence from long-term care insurance and Huntington disease. National Bureau of Economic Research Working Paper No.15326. September 2009. Available at www.nber.org/papers/w15326. Featured in NBER Bulletin on Aging and Health 2009;3:6 and The NBER Digest February 2010.

Conference Proceedings

1. Rajan B, Seidmann A, **Dorsey ER**, Biglan KM, Remnick J. Analyzing the clinical and competitive impact of telemedicine – experience with treating Parkinson disease patients via telemedicine. Proceedings of the 44th Annual Hawaii International Conference on System Sciences, January 11, 2011.

Other Publications

1. **Dorsey R**. Commentary on Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions by Goetz CG et al. Parkinson's Disease Monitor & Commentary. 2008;1:4.
2. Tanner CM, Brandabur M, Dorsey ER. Parkinson's disease: a global view. Parkinson Report. April 2008.
3. Deuel L, **Dorsey ER**. Randomized, controlled trial of ethyl-EPA in Huntington disease. The Marker – Huntington's Disease Society of America, 2009 May: p. 7.
4. Deuel L, **Dorsey ER**. Reporting clinical trial results to research participants in Huntington disease studies. The Marker – Huntington's Disease Society of America, 2009 May: p. 6, 9.
5. **Dorsey ER**. Equal pay for equal work?. The New Physician 2010;59. Available at <http://www.amsa.org/AMSA/Homepage/Publications/TheNewPhysician/2010/0110Perspectives.aspx>.

Abstracts

1. **Dorsey ER**, Jarjoura D, Rutecki GW. Controllable lifestyle and specialty choice: how much does gender contribute to decision making? Physician Health Conference, American Medical Association and Canadian Medical Association, Oak Brook, IL, October 14-16, 2004.
2. Siderowf A, **Dorsey ER**. The cost-effectiveness of screening for pre-symptomatic Parkinson's disease depends on the availability of neuroprotective therapies. *Movement Disorders* 2005;20 (Suppl 10):S83.
3. Noyes K, Daumer M, Dick A, **Dorsey R**, Holloway R, McCabe C, Miller D, Schwid S, Shih HC. Comparing Cost-Effectiveness Models for MS Disease-Modifying Agents: Different Inputs and Assumptions Produce Different Conclusions. 58th Annual Meeting of the American Academy of Neurology, April 5, 2006, San Diego, CA.
4. Noyes K, Daumer M, Dick A, **Dorsey R**, Holloway R, McCabe C, Miller D, Schwid S, Shih HC. Comparing apples with what: Different inputs and assumptions produce different conclusions in MS economic models. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. May 22, 2006, Philadelphia, PA.
5. Noyes K, Dick A, **Dorsey R**, Holloway R, Schwid S, Li C, Shih HC. Use of Prescription Medications and Medical Costs in Multiple Sclerosis. AcademyHealth Annual Research Meeting, June 25, 2006, Seattle, WA.
6. Raphael BA, **Dorsey ER**, Balcer LJ, Galetta SL. Predictors of future publication record and academic rank. *American Academy of Neurology*, October 9, 2006, Chicago, IL. *Ann of Neurology* 2006;60(Suppl 10):S31.
7. **Dorsey ER**, Thompson J, de Roulet J, Carrasco M, Holloway RG, Moses H. Financial anatomy of neuroscience research. *American Academy of Neurology*, October 9, 2006, Chicago, IL. *Ann of Neurology* 2006;60(Suppl 10):S64.
8. **Dorsey ER**, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson's disease in the most populous nations, 2005 – 2030. *Movement Disorders Society*, October 31, 2006, Kyoto, Japan. *Movement Disorders* 2006;21(Suppl 15):S483.
9. Mitsumoto J, **Dorsey ER**, Thompson JP, Griggs RC. Impact of the Orphan Drug Act on drug development. *Rare Diseases Clinical Research Network Meeting*, September 5, 2007, Washington, DC.
10. Oster E, **Dorsey ER**, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington Study Group PHAROS Investigators. Factors associated with the decision to pursue genetic testing in individuals at risk for Huntington disease. *World Congress on Huntington Disease*, September 10, 2007, Dresden, Germany.
11. Huntington Study Group TREND-HD Investigators (**Dorsey ER** corresponding author). A randomized, controlled trial of ethyl-EPA for the treatment of Huntington disease – preliminary results. *World Congress on Huntington Disease*, September 11, 2007, Dresden, Germany.
12. Biglan KM, **Dorsey ER**, Kieburtz K, Ross CA, Hersch S, Shoulson I, Matson W for the Pre2CARE Investigators of the Huntington Study Group. Serum 8OHdG levels in manifest Huntington disease and healthy controls treated with coenzyme Q₁₀. *World Congress on Huntington Disease*, September 11, 2007, Dresden, Germany.
13. **Dorsey ER**, Beck CA, Coles MA, Burns RS, Biglan KM. Survey of the Parkinson's Disease Registry. *Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders*. October 7, 2007, Washington, DC. *Movement Disorders* 2007;22:XV
14. **Dorsey ER**, Thompson JP, Nicholson S, Fiske B, Sherer T, Frasier M. Financial anatomy of Parkinson research. *Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders*. October 7, 2007, Washington, DC. *Movement Disorders* 2007;22:II-III
15. Thompson JP, Noyes K, **Dorsey ER**, Schwid SR, Holloway RG. A quantitative risk-benefit analysis of natalizumab. *Society for Medical Decision Making*, October 20-24, 2007, Pittsburgh, PA.
16. Oster E, **Dorsey ER**, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington Study Group PHAROS Investigators. Factors Associated with the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington Disease. *Huntington Disease Clinical Research Symposium*. December 1, 2007, Boston, MA. *Neurotherapeutics* 2008;5:368.
17. Huntington Study Group COHORT Investigators (Shoulson I, primary author; **Dorsey ER**, medical monitor). COHORT: A Snapshot of Baseline Characteristics. *Huntington Disease Clinical Research Symposium*. December 1, 2007, Boston, MA.
18. Huntington Study Group TREND-HD Investigators (**Dorsey ER**, corresponding author). A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington Disease – 12-Month Results. *Huntington Disease Clinical Research Symposium*. December 1, 2007, Boston, MA. *Neurotherapeutics* 2008;5:363.
19. **Dorsey ER**, Beck C, Adams M, Chadwick G, de Bleeck EA, McCallum C, Deuel L, Clarke A, Stewart R, Shoulson I, and the Huntington Study Group TREND-HD Investigators. Communicating Findings to Research Participants:

- Preliminary Results from the TREND-HD Study. Huntington Disease Clinical Research Symposium. December 1, 2007, Boston, MA. *Neurotherapeutics* 2008;5:374-5.
20. Shprecher DR, Beck CA, Coles MA, Voss TS, Deuel LM, Gardiner IF, Burns RS, Marshall FJ, Biglan KM, **Dorsey ER**. Support group use by individuals with Parkinson disease. *Movement Disorders* 2008;23(Suppl 1):S344.
 21. Voss TS, Beck CA, Coles MA, Shprecher DR, Deuel LM, Gardiner IF, Burns RS, Marshall FJ, Biglan KM, **Dorsey ER**. Patient care satisfaction in Parkinson's disease. *Movement Disorders* 2008;23(Suppl 1):S343-S344.
 22. **Dorsey ER**, Voss TS, Beck CA, Gardiner IF, Coles MA, Shprecher DR, Deuel LM, Scott J, Burns RS, Marshall FJ, Biglan KM. Group patient visits for Parkinson disease. *Movement Disorders* 2008; 23(Suppl 1):S345.
 23. Biglan KM, Voss TS, Eason S, Appler A, Viti L, Smith S, Miller D, Fagnano M, Deuel LM, Joseph A, **Dorsey ER**. Telemedicine visits for the management of Parkinson's disease. *Movement Disorders* 2008; 23(Suppl 1):S345-S346.
 24. Huntington Study Group COHORT Investigators (role: clinical monitor; corresponding author: Shoulson I). Cooperative Huntington observational research trial (COHORT): baseline mental health risks. Huntington Disease Clinical Research Symposium. November 15, 2008, St. Pete Beach, FL.
 25. The Huntington Study Group (role: site investigator; corresponding author: Kiebertz K). Dimebon in mild-to-moderate Huntington's Disease: a multi-center, phase 2, randomized, placebo-controlled trial. Huntington Disease Clinical Research Symposium. November 15, 2008, St. Pete Beach, FL.
 26. Block RC, **Dorsey ER**, Beck CA, Shoulson I for the Huntington Study Group TREND-HD Investigators. Triglyceride-lowering effects of EPA in individuals with Huntington disease. Huntington Disease Clinical Research Symposium. November 15, 2008, St. Pete Beach, FL.
 27. Oster E, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, **Dorsey ER** for the Huntington Study Group PHAROS Investigators. Insurance ownership and genetic risk. Huntington Disease Clinical Research Symposium. November 15, 2008, St. Pete Beach, FL.
 28. Biglan KM, Deuel L, Appler A, Joseph A, Miller D, Polanowicz J, Smith S, Viti L, **Dorsey ER**. The motor UPDRS assessed via telemedicine is reliable and valid. International Congress of Parkinson's Disease and Movement Disorders. Paris, France. June 7-11, 2009. *Movement Disorders* 2009;24(Suppl);S380.
 29. **Dorsey ER**, Deuel L, Appler A, Eason S, George B, Joseph A, Miller D, Polanowicz J, Reminick J, Smith S, Viti L, Voss T, Biglan K. Pilot randomized controlled trial of telemedicine for individuals with Parkinson disease. International Congress of Parkinson's Disease and Movement Disorders. Paris, France. June 7-11, 2009. *Movement Disorders* 2009;24(Suppl);S261.
 30. Oster E, Juhl AR, Erwin C, Williams JK, Mengling M, Mills JA, Bombard Y, Hayden MR, Shoulson I, Taylor S, **Dorsey ER**, Paulsen JS, the Huntington Study Group PREDICT-HD and PHAROS Investigators. Genetic discrimination in insurance: attitudes, behaviors and experiences. *Clinical Genetics* 2009;76(Suppl 1):J21.
 31. Oster E, Quaid K, Shoulson I, **Dorsey ER** for the Huntington Study Group PHAROS Investigators. Genetic adverse selection in long-term care insurance. *Clinical Genetics* 2009;76(Suppl 1):G09.
 32. Oster E, **Dorsey ER** on behalf of the Huntington Study Group COHORT Investigators. Preventive cancer screening among individuals in COHORT. Huntington Disease Clinical Research Symposium. October 15, 2010. La Jolla, CA.
 33. Conti RM, **Dorsey ER**, Rabbani A, Alexander GC. Effect of FDA advisories on pharmaceutical promotion of atypical antipsychotics to physicians and consumers. *American Society of Health Economics*. June 2010.
 34. Sohn A, **Dorsey ER**, Conti R, Huskamp HA, Dusetzina SB, Zhu S, Garfield CF, Alexander GC. Impact of FDA risk communications on health care utilization and health behaviors: a systematic review. Midwest Meeting of the Society of General Internal Medicine. Chicago, IL, September 2010.
 35. Kinel S, McCarthy L, Kayson E, **Dorsey ER**, Noonberg S, Vetter L, Goodman L. Project AWARE: Assessing Awareness, Willingness and Ability of the Huntington disease Community to participate in Huntington disease clinical trials. *Neurotherapeutics* 8[1]. 2011.
 36. George BP, Scoglio NJ, Reminick JI, Rajan B, Seidmann A, **Dorsey ER**, Biglan KM. Neurological care for nursing home residents with movement disorders. American Academy of Neurology 63rd Annual Meeting; Honolulu, Hawaii. April 9-16, 2011.
 37. Scoglio NJ, George BP, Reminick JI, Deuel LM, Rajan B, Seidmann A, Biglan KM, **Dorsey ER**. Providing specialty care to older individuals with chronic neurological conditions in their home. American Geriatrics Society Annual Scientific Meeting; National Harbor, MD. May 11-14, 2011.
 38. Abdolahi A, Scoglio N, **Dorsey ER**, Killoran A, Biglan KM. Potential reliability and validity of assessing the UPDRS remotely. 15th International Congress of Parkinson's Disease and Movement Disorders Meeting; Toronto, Canada. June 5-9, 2011.

39. Biglan KM, Killoran A, Scoglio N, Cayea-Delker S, Friedman V, Hadfield T, Rubens R, **Dorsey ER**. The generalizability of telemedicine for providing care to individuals with chronic neurological conditions residing in nursing homes. 15th International Congress of Parkinson's Disease and Movement Disorders Meeting: Toronto, Canada. June 5-9, 2011.

Teaching

2005	Small group leader, Neuroanatomy Course, first year medical students, University of Pennsylvania School of Medicine (Two month course [REDACTED])
2006-08	Small group co-leader, Ambulatory Clerkship Journal Club, second year medical students, University of Rochester School of Medicine (One month course [REDACTED])
2008	Lecturer, Academic Career Development Course, geriatric fellows, University of Rochester School of Medicine (2 lectures [REDACTED])
2008-10	Lecturer, Process of Discovery Course, second and fourth year medical students, University of Rochester School of Medicine (2 lectures per year [REDACTED])
2008-10	Lecturer, Academic Research Track, first year medical students, University of Rochester School of Medicine (1 lecture per year [REDACTED])
2010	Lecturer, Diseases and disorders of the nervous system, undergraduate neuroscience majors, Johns Hopkins University (1 lecture [REDACTED])

Mentoring

2006-present	Mentor to several undergraduate, public health, medical students, and residents interested in health services research (Over 10 students. Eight have published their first peer-reviewed paper under my mentorship including 6 in <i>JAMA</i> . Three have received extramural funding for their research under my guidance and three have matriculated in medical school.)
2006-present	[REDACTED] currently a medical student at the University at Buffalo
2006-07	[REDACTED] currently a neurologist in community practice
2006-08	[REDACTED] currently a MD/Ph.D. student at the University of Rochester/University of Michigan
2006-09	[REDACTED] currently a medicine resident at Case Western University
2007-2009	[REDACTED], currently a medical student at the University of Michigan
2007-present	[REDACTED], currently a medical student at the University of Rochester
2008	[REDACTED], currently a medical student at Columbia University
2008-present	[REDACTED] currently a MD/MBA student at the University of Rochester
2009	[REDACTED], currently an undergraduate at the University of Rochester
2009	[REDACTED] currently a research assistant at Johns Hopkins

Thesis Committee Member

2006	Master's degree in public health, thesis committee member for [REDACTED]
2008-present	Master's degree in public health, thesis committee member for [REDACTED]

Training Grant Participation

2007-10	Fellowship director, NIH-funded T32 Experimental Therapeutics Fellowship (up to 4 fellows per year)
---------	---

Educational Program Building/Leadership

2010-present	Co-founder and lecturer, Medical Entrepreneurship, University of Rochester School of Medicine and Simon School of Business (co-created elective for ~20 medical and business school students who as part of the course created and presented their own business plan for improving health care)
--------------	---

CLINICAL ACTIVITIES

Certification

Licensed Physician, State of Maryland. License# [REDACTED]
 Licensed Physician, State of New York. License# [REDACTED]
 Licensed Physician, State of California. License# [REDACTED]

Certified, Human Subject Protection Program (HSPP) [REDACTED]
Diplomate, American Board of Psychiatry and Neurology, Inc., [REDACTED]

Clinical (Service) Responsibilities

2006-10 Neurology inpatient and consult attending at Strong Memorial Hospital (4 weeks per year)
2006-10 Neurology attending in movement disorder clinic at the University of Rochester (1 day per week)
2010-present Neurology inpatient and consult attending at Johns Hopkins Hospital (4-6 weeks per year)
2010-present Neurology attending in movement disorder clinic at Johns Hopkins (1 day per week)

Clinical Program Building/Leadership

2007-present Co-founder of a telemedicine program to deliver specialty care to individuals with Parkinson disease and other movement disorders in nursing homes and in their homes – “virtual house calls” (Effort initiated with [REDACTED])

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

2008-present Executive Committee member, Huntington Study Group
2008-present Director, Huntington Study Group Coordination Center
2009-present Member, American Academy of Neurology Investment Committee

Other Administrative Appointments

2002-03 Member, Board of Directors, National Depressive and Manic Depressive Association (now Depression and Bipolar Support Alliance)
2003-04 Member, Finance subcommittee, Depression and Bipolar Support Alliance
2005 Intern to CEO of University of Pennsylvania Health System ([REDACTED]), improving patient access
2008-present Member, Parkinson Disease Expert Group, World Health Organization, to help determine the global burden of Parkinson disease

Journal Peer Review

Ad hoc reviewer for *Academic Medicine*, *Applied Health Economics and Health Policy*, *Archives of Internal Medicine*, *Archives of General Psychiatry*, *Archives of Neurology*, *European Journal of Neurology*, *Health Affairs*, *JAMA*, *Journal of Health Politics, Policy and Law*, *Movement Disorders*, *Neural Regeneration Research*, *Neuroepidemiology*, *Neurology*, *Parkinsonism & Related Disorders*, *Pediatrics*, and *Value in Health*.

Grant Peer Review

[REDACTED]

November 2-3, 2009 National Institute for Neurological Disorders and Stroke Clinical Trials Study Section (NSD-K), ad hoc reviewer

Federal Service

October 8, 2010 Ad hoc panel member, U.S. Food and Drug Administration, Neurological Devices Advisory Panel
January 2011-present Committee member, Institute of Medicine Committee on Cognitive Rehabilitation Therapy for Traumatic Brain Injury

Professional Society Membership

2007-present Member, Movement Disorders Society
2007-present Member, American Academy of Neurology
2009-present Member, American Society for Experimental Neurotherapeutics

Conference Organizer

2008 Co-chair, Huntington Study Group Site Management Course, St. Pete Beach, Florida
2008-09 Program committee, Robert Wood Johnson Foundation Physician Faculty Scholars 2008 and 2009 national meetings

Consultantships

2005-2007 Strategic advisor, Avid Radiopharmaceuticals, Inc.
2009-present Consultant to Lundbeck, Inc.
2009-present Consultant to Medtronic

RECOGNITION

Awards

1998 Director's List, The Wharton School
1999 Dr. Eric C. Raps' Memorial Award for Excellence in Clinical Neurology, University of Pennsylvania School of Medicine
Intern of the Year, Evanston Hospital, Evanston Northwest Healthcare
Education Research Award, Department of Neurology, University of Pennsylvania Medical Center
American Academy of Neurology Clinical Research Training Fellowship
2006 Best clinical abstract, University of Rochester Neurology and Neurosurgery Symposium
Mentor to [REDACTED]
[REDACTED]
2007 Best abstract for Parkinson's disease session, 21st Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's disease and Other Movement Disorders
2008 Robert Wood Johnson Foundation Physician Faculty Scholar
2009 *Academic Medicine* Excellence in Reviewing Award
2010 American Academy of Neurology's Jon Stolk Award in Movement Disorders for Young Investigators

Invited National and International Presentations

September 10, 2007 Factors associated with the decision to pursue genetic testing in individuals at risk for Huntington disease. World Congress on Huntington's Disease. Dresden, Germany
September 11, 2007 A randomized, controlled trial of ethyl-EPA for the treatment of Huntington's disease – preliminary results. World Congress on Huntington's Disease. Dresden, Germany.
October 6, 2007 Non-NIH funding. National Institutes of Neurological Disease and Stroke and American Neurological Association Career Development Symposium. Washington, DC.
October 7, 2007 Financial anatomy of Parkinson research. 21st Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders. Washington, DC.
October 8, 2007 Growing global burden of neurological disease. American Neurological Association. Washington, DC.
December 1, 2007 A randomized, controlled trial of ethyl-EPA for the treatment of Huntington disease – 12-month results. Inaugural Huntington Disease Clinical Research Symposium. Boston, MA.
February 18, 2009 Economics of new faculty hires in basic science. Council on Governmental Relations. Washington DC.
March 13, 2009 Clinical research opportunities at NINDS. National Institute of Neurological Disorders. Bethesda, MD.
September 15, 2009 Communicating clinical trial results to research participants. World Congress on Huntington's Disease. Vancouver, British Columbia.
November 3, 2009 Reducing the burden of Alzheimer and Parkinson disease. Alliance on Aging Research presentation to Congressional staffers. Washington, DC.
April 13, 2010 Improving access to neurological care. Jon Stolk Award Presentation. American Academy of Neurology, Toronto, Canada.
October 14, 2010 Genetic adverse selection in long-term care insurance. Huntington Study Group annual meeting. La Jolla, CA
October 15, 2010 Telemedicine and movement disorders with [REDACTED]. Huntington Study Group annual meeting. La Jolla, CA

March 16, 2011 Telemedicine for neurological disorders, including traumatic brain injury. Institute of Medicine Committee on Cognitive Rehabilitation Therapy for Traumatic Brain Injury. Irvine, CA

Invited University Presentations

October 5, 2007 Growing global burden of neurological disease. University of Rochester Department of Neurology 40th Anniversary. Rochester, NY.

July 1, 2009 Impact of FDA black box warnings on atypical anti-psychotic use. The University of Chicago Department of Medicine Research in Progress Seminar. Chicago, IL.

December 18, 2009 Local IRB review of a multicenter trial: local costs without local context. With [REDACTED] and [REDACTED]. Working group on clinical trials. University of Rochester, Rochester, NY.

February 12, 2010 Increasing access to neurologists via telemedicine. With [REDACTED]. University of Rochester Department of Neurology Grand Rounds, Rochester, NY.

March 18, 2010 Improving access to neurologists via telemedicine. University of Pennsylvania Department of Neurology Grand Rounds, Philadelphia, PA.

September 16, 2010 Hopkins@Home – providing patient-centered care anywhere. Johns Hopkins University Division of Geriatrics Grand Rounds, Baltimore, MD.

November 4, 2010 Extending our reach – providing patient-centered neurological care anywhere. Johns Hopkins University Department of Neurology Grand Rounds, Baltimore, MD.

Other Presentations

March 22, 2010 Telemedicine and Parkinson disease: improving care and clinical research with [REDACTED] Google Tech Talk. Mountain View, CA.

June 11, 2010 Telemedicine and Parkinson disease: improving care and clinical research with [REDACTED] Marvell company presentation. Santa Clara, CA.

March 19, 2011 Providing patient-centered care for Parkinson disease anywhere. Parkinson Foundation National Capital Association. Bethesda, MD.

March 31, 2011 Innovating for Life: Changing the way healthcare is delivered for Parkinson disease. Medtronic. Minneapolis, MN.